Cancer risk in patients receiving renal replacement therapy: A meta-analysis of cohort studies

Shang,Weifeng; Huang,Liu; Li,Li; Li,Xiaojuan; Zeng,Rui; Ge,Shuwang; Xu,Gang

doi:10.3892/mco.2016.952

Cancer risk in patients receiving renal replacement therapy: A meta-analysis of cohort studies

Authors:
- Weifeng Shang
- Liu Huang
- Li Li
- Xiaojuan Li
- Rui Zeng
- Shuwang Ge
- Gang Xu
View Affiliations

Affiliations: Department of Nephrology, Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Oncology, Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Clinical Nutrition, Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: July 7, 2016 https://doi.org/10.3892/mco.2016.952
Pages: 315-325

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that patients receiving renal replacement therapy (RRT), including dialysis and kidney transplantation, tend to have an increased risk of cancer; however, studies on the degree of this risk have remained inconclusive. The present meta-analysis was therefore performed to quantify the cancer risk in patients with RRT. Cohort studies assessing overall cancer risk in RRT patients published before May 29, 2015 were included following systematic searches with of PubMed, EMBASE and the reference lists of the studies retrieved. Random-effects meta‑analyses were used to pool standardized incidence rates (SIRs) with 95% confidence intervals (CIs). Heterogeneity tests, sensitivity analyses and publication bias assessment were performed. A total of 18 studies including 22 cohort studies were eventually identified, which comprised a total of 1,528,719 patients. In comparison with the general population, the pooled SIR for patients with dialysis including non‑melanoma skin cancer (NMSC), dialysis excluding NMSC, transplantation including NMSC, transplantation excluding NMSC and RRT were 1.40 (95% CI, 1.36-1.45), 1.35 (95% CI, 1.23-1.50), 3.26 (95% CI, 2.29-4.63), 2.08 (95% CI, 1.73-2.50) and 2.01 (95% CI, 1.70-2.38), respectively. The cancer risk was particularly high in subgroups of large sample size trials, female patients, younger patients (age at first dialysis, 0-34 years; age at transplantation, 0-20 years), the first year of RRT and non‑Asian transplant patients. A significant association was also found between RRT and the majority of organ‑specific cancers. However, neither dialysis nor transplantation was associated with breast, body of uterus, colorectal or prostate cancer. Significant heterogeneity was found regarding the association between RRT and overall cancer as well as the majority of site‑specific cancer types. However, this heterogeneity had no substantial influence on the pooled SIR for overall cancer in RRT according to the sensitivity analysis. Compared with the general population, RRT patients have a significantly increased risk of overall cancer and the majority of specific cancer types, particularly Kaposi sarcoma (KS), lip cancer and NMSC in patients subjected to kidney transplantation and cancer of the thyroid gland and kidney as well as myeloma in dialysis patients. Considering the high heterogeneity encountered, further high-quality studies are required.

View Figures

View References

1	Collins AJ, Foley RN, Gilbertson DT and Chen SC: The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 4(Suppl 1): S5–S11. 2009. View Article : Google Scholar : PubMed/NCBI
2	Mandayam S and Shahinian VB: Are chronic dialysis patients at increased risk for cancer? J Nephrol. 21:166–174. 2008.PubMed/NCBI
3	Briggs JD: Causes of death after renal transplantation. Nephrol Dial Transplant. 16:1545–1549. 2001. View Article : Google Scholar : PubMed/NCBI
4	Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM and Grulich AE: Cancer incidence before and after kidney transplantation. JAMA. 296:2823–2831. 2006. View Article : Google Scholar : PubMed/NCBI
5	Penn I and Starzl TE: Malignant lymphomas in transplantation patients: A review of the world experience. Int J Clin Pharmacol Ther Toxicol. 3:49–54. 1970.
6	Marple JT and MacDougall M: Development of malignancy in the end-stage renal disease patient. Semin Nephrol. 13:306–314. 1993.PubMed/NCBI
7	Grulich AE, van Leeuwen MT, Falster MO and Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet. 370:59–67. 2007. View Article : Google Scholar : PubMed/NCBI
8	Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE and McCredie MR: The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 24:3225–3231. 2009. View Article : Google Scholar : PubMed/NCBI
9	Lin HF, Li YH, Wang CH, Chou CL, Kuo DJ and Fang TC: Increased risk of cancer in chronic dialysis patients: A population-based cohort study in Taiwan. Nephrol Dial Transplant. 27:1585–1590. 2012. View Article : Google Scholar : PubMed/NCBI
10	Loy EY, Choong HL and Chow KY: Cancer among end-stage renal disease patients on dialysis. Ann Acad Med Singapore. 42:640–645. 2013.PubMed/NCBI
11	Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB and Brookhart MA: Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis. 65:763–772. 2015. View Article : Google Scholar : PubMed/NCBI
12	Collett D, Mumford L, Banner NR, Neuberger J and Watson C: Comparison of the incidence of malignancy in recipients of different types of organ: A UK registry audit. Am J Transplant. 10:1889–1896. 2010. View Article : Google Scholar : PubMed/NCBI
13	Li WH, Chen YJ, Tseng WC, Lin MW, Chen TJ, Chu SY, Hwang CY, Chen CC, Lee DD, Chang YT, et al: Malignancies after renal transplantation in Taiwan: A nationwide population-based study. Nephrol Dial Transplant. 27:833–839. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cheung CY, Lam MF, Chu KH, Chow KM, Tsang KY, Yuen SK, Wong PN, Chan SK, Leung KT, Chan CK, et al: Malignancies after kidney transplantation: Hong Kong renal registry. Am J Transplant. 12:3039–3046. 2012. View Article : Google Scholar : PubMed/NCBI
15	Piselli P, Serraino D, Segoloni GP, et al: Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer. 49:336–344. 2013. View Article : Google Scholar : PubMed/NCBI
16	Krynitz B, Edgren G, Lindelöf B, Baecklund E, Brattström C, Wilczek H and Smedby KE: Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008 - a Swedish population-based study. Int J Cancer. 132:1429–1438. 2013. View Article : Google Scholar : PubMed/NCBI
17	Stengel B: Chronic kidney disease and cancer: A troubling connection. J Nephrol. 23:253–262. 2010.PubMed/NCBI
18	Izzedine H and Perazella MA: Onco-nephrology: An appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant. 30:1979–1988. 2015. View Article : Google Scholar : PubMed/NCBI
19	Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI
20	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
21	Egger M, Smith Davey G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
22	Port FK, Ragheb NE, Schwartz AG and Hawthorne VM: Neoplasms in dialysis patients: A population-based study. Am J Kidney Dis. 14:119–123. 1989. View Article : Google Scholar : PubMed/NCBI
23	Birkeland SA, Løkkegaard H and Storm HH: Cancer risk in patients on dialysis and after renal transplantation. Lancet. 355:1886–1887. 2000. View Article : Google Scholar : PubMed/NCBI
24	Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T and Aozasa K: Cancer risk after renal transplantation in Japan. Int J Cancer. 71:517–520. 1997. View Article : Google Scholar : PubMed/NCBI
25	Kyllönen L, Salmela K and Pukkala E: Cancer incidence in a kidney-transplanted population. Transpl Int. 13(Suppl 1): S394–S398. 2000. View Article : Google Scholar : PubMed/NCBI
26	Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO and Granath F: Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer. 89:1221–1227. 2003. View Article : Google Scholar : PubMed/NCBI
27	Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E, Tóth A, Perner F and Járay J: Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 13:63–69. 2007. View Article : Google Scholar : PubMed/NCBI
28	Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y and Mao Y: Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 7:941–948. 2007. View Article : Google Scholar : PubMed/NCBI
29	Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, Baccarani U, De Juli E, Pozzetto U, Bellelli S, et al: Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 43:2117–2123. 2007. View Article : Google Scholar : PubMed/NCBI
30	Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, et al: Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet. 354:93–99. 1999. View Article : Google Scholar : PubMed/NCBI
31	Yan L, Chen P, Chen EZ, Gu A and Jiang ZY: Risk of bladder cancer in renal transplant recipients: A meta-analysis. Br J Cancer. 110:1871–1877. 2014. View Article : Google Scholar : PubMed/NCBI
32	Yang Z, Lin F, Qin B, Liang Y and Zhong R: Polymyositis/dermatomyositis and malignancy risk: A metaanalysis study. J Rheumatol. 42:282–291. 2015. View Article : Google Scholar : PubMed/NCBI
33	Heidland A, Bahner U and Vamvakas S: Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis. 35:347–351; discussion 352–353. 2000. View Article : Google Scholar : PubMed/NCBI
34	Vamvakas S, Bahner U and Heidland A: Cancer in end-stage renal disease: Potential factors involved-editorial. Am J Nephrol. 18:89–95. 1998. View Article : Google Scholar : PubMed/NCBI
35	Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 306:1891–1901. 2011. View Article : Google Scholar : PubMed/NCBI
36	Marple JT, MacDougall M and Chonko AM: Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol. 4:1951–1956. 1994.PubMed/NCBI
37	Taylor AE and Shuster S: Skin cancer after renal transplantation: The causal role of azathioprine. Acta Derm Venereol. 72:115–119. 1992.PubMed/NCBI
38	Silman AJ, Petrie J, Hazleman B and Evans SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis. 47:988–992. 1988. View Article : Google Scholar : PubMed/NCBI
39	Vamvakas S, Bahner U, Becker P, Steinle A, Götz R and Heidland A: Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc. 28:3468–3473. 1996.PubMed/NCBI
40	Yoshimura S, Suemizu H, Nomoto Y, Sakai H, Katsuoka Y, Kawamura N and Moriuchi T: Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron. 73:207–211. 1996. View Article : Google Scholar : PubMed/NCBI
41	Akizawa T, Kinugasa E and Koshikawa S: Increased risk of malignancy and blood-membrane interactions in uraemic patients. Nephrol Dial Transplant. 9(Suppl 2): S162–S164. 1994.
42	Gutierrez-Dalmau A and Campistol JM: Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs. 67:1167–1198. 2007. View Article : Google Scholar : PubMed/NCBI